You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)治療關節炎藥物塞來昔布膠囊獲藥品註冊批件
格隆匯 01-09 16:32

格隆匯1月9日丨中國生物製藥(01177.HK)公佈,由公司附屬公司江蘇正大清江製藥有限公司開發的治療關節炎藥物塞來昔布膠囊,已獲中國國家藥品監督管理局頒發藥品註冊批件。該產品為國內同品種第二家獲批,且被視同通過仿製藥質量和療效一致性評價。

塞來昔布為選擇性環氧化酶-2(COX-2)抑制劑類非甾體抗炎藥,用於緩解骨關節炎的症狀和體徵、緩解成人類風濕關節炎的症狀和體徵、治療成人急性疼痛等。目前,國內市場上僅有原研產品在售。該集團開發的塞來昔布膠囊此次獲批上市,將進一步豐富該集團的產品組合,有助於該集團在骨科用藥領域的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account